-
Apr 09, 2020
F-star Therapeutics Announces Data on Potent Anti-Tumor Activity of FS120 Published in Cancer Immunology Research -
Feb 20, 2020
F-star Therapeutics to Participate in the BTIG Targeted Therapeutics Conference -
Jan 30, 2020
F-star Therapeutics Announces FDA Acceptance of IND Application for FS120 -
Jan 09, 2020
F-star Therapeutics Appoints Dr. Edward Benz and Mr. Geoff Race to Board of Directors -
Nov 08, 2019
F-star Presents New Data on OX40/CD137 Tetravalent Bispecific Antibody at the SITC 2019 Annual Meeting -
Jun 18, 2019
F-star appoints Darlene Deptula-Hicks as CFO -
Jun 10, 2019
F-star appoints Dr Louis Kayitalire as CMO -
May 30, 2019
F-star updates on FS118 clinical trial and announces presentation at ASCO 2019 -
May 14, 2019
F-star expedites its transition to a wholly-owned portfolio strategy -
Mar 25, 2019
F-star Presents New Data on its Tetravalent Bispecific Antibodies at the AACR 2019 Annual Meeting
Pagination
